MedWorm: Rheumatology Clinical Trials

A Double-Blind Study Evaluating IPI-145 in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone

ClinicalTrials.gov — Wed, 08 May 2013 16:00:00 +0100

Condition: Rheumatoid ArthritisInterventions: Drug: IPI-145; Drug: PlaceboSponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.Recruiting - verified May 2013 (Source: ClinicalTrials.gov)

MedWorm Sponsor Message: Have a look at The Rheumatology Daily, the new rheumatology portal powered by MedWorm, with all the latest rheumatology news and research updated daily.

A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid Arthritis

ClinicalTrials.gov — Thu, 11 Apr 2013 16:00:00 +0100

Condition: Rheumatoid ArthritisIntervention: Sponsors: Hoffmann-La Roche; Hoffmann-La RocheRecruiting - verified April 2013 (Source: ClinicalTrials.gov)

Efficacy and Safety Study of TissueGene-C Mixed With Fibrin-glue for the Patients With Degenerative Arthritis

ClinicalTrials.gov — Wed, 03 Apr 2013 16:00:00 +0100

Condition: Degenerative ArthritisInterventions: Biological: TisssueGene-C (Low dose); Biological: TisssueGene-C (High dose)Sponsors: Kolon Life Science; Kolon Life ScienceRecruiting - verified April 2013 (Source: ClinicalTrials.gov)

The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis

ClinicalTrials.gov — Wed, 20 Mar 2013 16:00:00 +0100

Condition: Psoriatic ArthritisInterventions: Dietary Supplement: n-3PUFA; Dietary Supplement: olive oilSponsors: Aalborg Universityhospital; Aalborg UniversityhospitalRecruiting - verified March 2013 (Source: ClinicalTrials.gov)

Rheumatology Clinical Registry

ClinicalTrials.gov — Fri, 15 Mar 2013 16:00:00 +0100

Condition: Rheumatoid ArthritisIntervention: Sponsors: American College of Rheumatology; American College of RheumatologyRecruiting - verified March 2013 (Source: ClinicalTrials.gov)

Effect of Andosan in Patients With Rheumatoid Arthritis

ClinicalTrials.gov — Thu, 14 Mar 2013 16:00:00 +0100

Condition: Rheumatoid ArthritisIntervention: Dietary Supplement: Mushroom extractSponsors: Oslo University Hospital; Egil Johnson; ImmunoPharmaNot yet recruiting - verified March 2013 (Source: ClinicalTrials.gov)

Brigham and Women's Rheumatoid Arthritis Sequential Study

ClinicalTrials.gov — Thu, 14 Feb 2013 17:00:00 +0100

Condition: Rheumatoid ArthritisIntervention: Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Crescendo Bioscience; MedImmune LLC; Bristol-Myers SquibbRecruiting - verified February 2013 (Source: ClinicalTrials.gov)

ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis

ClinicalTrials.gov — Tue, 12 Feb 2013 17:00:00 +0100

Condition: Rheumatoid ArthritisIntervention: Sponsors: Hoffmann-La Roche; Hoffmann-La RocheNot yet recruiting - verified February 2013 (Source: ClinicalTrials.gov)

Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients

ClinicalTrials.gov — Wed, 30 Jan 2013 17:00:00 +0100

Conditions: Pelubiprofen; Celebrex; Rheumatoid ArthritisInterventions: Drug: Pelubiprofen 30 mg; Drug: Celebrex 200 mgSponsors: Daewon Pharmaceutical Co., Ltd.; Daewon Pharmaceutical Co., Ltd.Completed - verified January 2013 (Source: ClinicalTrials.gov)

RA Denosumab on Bone Microstructure Study

ClinicalTrials.gov — Thu, 03 Jan 2013 17:00:00 +0100

Condition: Rheumatoid ArthritisInterventions: Drug: Denosumab; Drug: AlendronateSponsors: Chinese University of Hong Kong; Chinese University of Hong KongNot yet recruiting - verified January 2013 (Source: ClinicalTrials.gov)

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis

ClinicalTrials.gov — Fri, 21 Dec 2012 17:11:10 +0100

Condition: Rheumatoid ArthritisInterventions: Drug: ASP015K; Drug: MethotrexateSponsors: Astellas Pharma Inc; Astellas Pharma IncCompleted - verified December 2012 (Source: ClinicalTrials.gov)

NEJM Published Study shows Novartis Compound ACZ885 Significantly Relieves Symptoms in Patients with Serious Form of Childhood Arthritis

Drugs.com - Clinical Trials — Thu, 20 Dec 2012 10:57:57 +0100

- Endpoints met in two Phase III trials, including substantial symptom relief in 84% of systemic juvenile idiopathic arthritis (SJIA) patients treated with ACZ885 in trial-11 - SJIA patients treated with ACZ885 in trial-2 were nearly three times... (Source: Drugs.com - Clinical Trials)

MedWorm Sponsor Message: Have a look at The Rheumatology Daily, the new rheumatology portal powered by MedWorm, with all the latest rheumatology news and research updated daily.

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis

ClinicalTrials.gov — Wed, 19 Dec 2012 17:00:00 +0100

Condition: Rheumatoid ArthritisInterventions: Drug: ASP015K; Drug: MethotrexateSponsors: Astellas Pharma Inc; Astellas Pharma IncCompleted - verified December 2012 (Source: ClinicalTrials.gov)

AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis

Drugs.com - Clinical Trials — Thu, 13 Dec 2012 12:50:13 +0100

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2012 /PRNewswire/ -- AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in... (Source: Drugs.com - Clinical Trials)

The Predictive Value of Ultrasound in Early Rheumatoid Arthritis

ClinicalTrials.gov — Wed, 12 Dec 2012 17:00:00 +0100

Conditions: Rheumatoid Arthritis; Predictive Value of Ultrasound in Early Rheumatoid ArthritisIntervention: Sponsors: Erasmus Medical Center; Erasmus Medical Center; Maasstad Hospital; Albert Schweitzer Hospital; Vlietland Hospital Schiedam; UMC Utrecht; Medical Center Alkmaar; Ziekenhuisgroep TwenteRecruiting - verified December 2012 (Source: ClinicalTrials.gov)

UCB Announces Data on Cimzia (certolizumab pegol) for Patients with Moderate to Severe Rheumatoid Arthritis at American College of Rheumatology 2012 Congress

Drugs.com - Clinical Trials — Wed, 14 Nov 2012 00:04:28 +0100

-- A post-hoc analysis of the DOSEFLEX study demonstrated efficacy in maintenance of clinical response versus placebo for two doses of certolizumab pegol in patients with and without prior anti-TNF therapy -- Findings from five-year open-label study... (Source: Drugs.com - Clinical Trials)

Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis

Drugs.com - Clinical Trials — Tue, 13 Nov 2012 23:35:18 +0100

- Baricitinib advancing into Phase III trials for rheumatoid arthritis - Lilly and Incyte to host a webcast for investors featuring these results today, Nov. 13 at 7 p.m. ET WASHINGTON, Nov. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)... (Source: Drugs.com - Clinical Trials)

Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of ACR20 in the First Phase III Study (PALACE-1) in Patients with Psoriatic Arthritis

Drugs.com - Clinical Trials — Tue, 13 Nov 2012 21:36:03 +0100

Apremilast significantly improves signs and symptoms of PsA in DMARDs-failure patients, including biologic-treatment-failure patients Apremilast monotherapy demonstrates robust improvement across primary and secondary endpoints Highest response... (Source: Drugs.com - Clinical Trials)

Preliminary Findings From Rheumatoid Arthritis Patient Survey Reveal Strong Interest in Needle-Free Self-Injection

Drugs.com - Clinical Trials — Tue, 13 Nov 2012 13:29:28 +0100

Survey Finds RA Patients' Willingness to Accept Prescriptions for Self-Injected Medication Substantially Increases if Needle-Free Option Available COLUMBUS, Ohio and SAN DIEGO, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Battelle, the world's largest... (Source: Drugs.com - Clinical Trials)

MedWorm Sponsor Message: Have a look at The Rheumatology Daily, the new rheumatology portal powered by MedWorm, with all the latest rheumatology news and research updated daily.

New Phase 3 Findings Show Stelara Significantly Reduced Signs and Symptoms of Active Psoriatic Arthritis

Drugs.com - Clinical Trials — Tue, 13 Nov 2012 13:29:06 +0100

STELARA® Continued to Provide Benefit in Psoriatic Arthritis Signs and Symptoms through Week 52 in One Phase 3 Trial TORONTO, November 12, 2012 – Janssen Inc. announced today recent findings from PSUMMIT II, a Phase 3... (Source: Drugs.com - Clinical Trials)

Long-Term Efficacy and Safety Results of Epratuzumab in Lupus Presented at Rheumatology Conference

Drugs.com - Clinical Trials — Tue, 13 Nov 2012 12:56:05 +0100

WASHINGTON, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious... (Source: Drugs.com - Clinical Trials)

GLPG0634 single center Proof of Concept results to be presented at American College of Rheumatology Annual meeting

Drugs.com - Clinical Trials — Mon, 12 Nov 2012 13:47:58 +0100

Mechelen, Belgium; 11 November 2012 - Galapagos NV (Euronext: GLPG) announced today that the single center Proof of Concept results from 2011 in rheumatoid arthritis with selective JAK1 inhibitor GLPG0634 will be presented during the American... (Source: Drugs.com - Clinical Trials)

ADACTA Study Showed Actemra Improved Signs and Symptoms of Rheumatoid Arthritis Significantly More Than Adalimumab as a Single-Agent Therapy

Drugs.com - Clinical Trials — Mon, 12 Nov 2012 12:31:12 +0100

-- In addition, data from 17 ACTEMRA studies, including ADACTA, to be presented at ACR Annual Meeting -- WASHINGTON--(BUSINESS WIRE)--Nov 10, 2012 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that results... (Source: Drugs.com - Clinical Trials)